Exploring the Decreasing Incidence of Colon Cancer in Those Over the Age of 50
August 18th 2017Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, discusses the decreasing incidence of colon cancer diagnosis in those over the age of 50.
Watch
Challenges With PARP Inhibitors in Ovarian Cancer
August 16th 2017Kathleen N. Moore, MD, assistant professor in the section of gynecologic oncology and director of the Oklahoma TSET Phase I Clinical Trials Program at the University of Oklahoma Health Sciences Center, discusses challenges with PARP inhibitors in ovarian cancer.
Watch
Phase II Results for Cabozantinib in RET-Rearranged Lung Cancer
August 14th 2017Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.
Watch
Dr. Lonial Discusses the Importance of Partnering With a Myeloma Center
August 14th 2017Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the importance of partnering with a myeloma center when managing multiple myeloma.
Watch
Exploring the Combination of Epacadostat and Pembrolizumab in Urothelial Carcinoma
August 8th 2017Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology and director of genitourinary research at Fox Chase Cancer Center in Philadelphia, discusses the combination of epacadostat and pembrolizumab (Keytruda) for the treatment of patients with urothelial carcinoma.
Watch
CAR T-Cell Therapy for Myeloma and Other Hematologic Malignancies
August 7th 2017Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses CAR T-cell therapy for myeloma and other hematologic malignancies.
Watch
Toxicities Associated with PARP Inhibitors in Ovarian Cancer
August 2nd 2017Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses the toxicities that are associated with PARP inhibitors in ovarian cancer.
Watch